Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$108.13 USD

108.13
1,465,958

+1.35 (1.26%)

Updated Jul 5, 2024 04:00 PM ET

After-Market: $108.20 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Makes Novartis (NVS) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Verizon Communications & United Parcel Service

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).

Here's Why Novartis (NVS) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks.com featured highlights include PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger

by Zacks Equity Research

PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger are part of the Zacks Screen of the Week article.

Sweta Killa headshot

5 Dividend Growth Stocks to Buy for Safe Returns

by Sweta Killa

PulteGroup (PHM), Novartis (NVS), Boyd Gaming (BYD), Cummins (CMI) and W.W. Grainger (GWW) could be solid choices for your portfolio.

Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues

by Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) reports better-than-expected first-quarter 2023 results. Givlaari, Oxlumo and the newly approved Amvuttra drive revenues for the company.

Novartis (NVS) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.

AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform

by Zacks Equity Research

AbbVie's (ABBV) first-quarter 2023 earnings and sales beat estimates. However, share price dives as some key drugs miss sales estimates.

Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?

by Zacks Equity Research

Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Novartis (NVS) Tops on Q1 Earnings & Revenues, Ups View

by Zacks Equity Research

Novartis (NVS) beats on earnings and sales in the first quarter, and raises its annual guidance on strong momentum.

Novartis (NVS) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo

by Zacks Equity Research

Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Are Medical Stocks Lagging Novo Nordisk (NVO) This Year?

by Zacks Equity Research

Here is how Novo Nordisk (NVO) and Novartis (NVS) have performed compared to their sector so far this year.

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Amgen (AMGN) Wins Patent Appeal for Blockbuster Psoriasis Drug

by Zacks Equity Research

The Appeal Court's decision upholding the patents for Amgen's (AMGN) blockbuster psoriasis drug Otezla will prevent drug-makers from selling a generic version till February 2028.

Here's Why Novartis (NVS) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Are You Looking for a High-Growth Dividend Stock?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks

by Zacks Equity Research

Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.

Bristol Myers' (BMY) Breyanzi Gets Positive CHMP Opinion

by Zacks Equity Research

Bristol Myers (BMY) receives a positive CHMP opinion for CAR T cell therapy with Breyanzi for relapsed or refractory large B-cell lymphoma after one prior treatment.

Novartis (NVS) Gets CHMP Positive Opinion for Entresto Approval

by Zacks Equity Research

Novartis (NVS) receives a positive opinion from the CHMP for Entresto (sacubitril/valsartan) for a new indication in pediatric patients.

Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why

by Zacks Equity Research

Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.

Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why

by Zacks Equity Research

Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.

Why Novartis (NVS) is a Great Dividend Stock Right Now

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.